Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Frontline Lenalidomide for AL Amyloidosis Involving Myocardium: Investigation of Organ Reversing Capacity of Lenalidomide

NCT04298372 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT04298372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04298372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Frontline Lenalidomide for AL Amyloidosis Involving Myocardium: Investigation of Organ Reversing Capacity of Lenalidomide
Lead sponsor
Seoul National University Hospital
Phase
Phase 3
Overall status
Completed
Start date
February 20, 2019
Completion date
November 25, 2021
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

amyloidosis cardiac